Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.
The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
Becker
Richard C
RC
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA. becke021@mc.duke.edu
Scheiman
James
J
Dauerman
Harold L
HL
Spencer
Frederick
F
Rao
Sunil
S
Sabatine
Marc
M
Johnson
David A
DA
Chan
Frances
F
Abraham
Neena S
NS
Quigley
Eamonn M M
EM
D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000628:therapy; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects; D006470:Hemorrhage / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000209:etiology
D010975:Platelet Aggregation Inhibitors